PRESS RELEASE published on 01/22/2024 at 15:00, 1 year 10 months ago Knockaround Sunglasses Announces Partnership With PGA Champion Joel Dahmen and Caddie Geno Bonnalie Knockaround has announced its partnership with professional golfer Joel Dahmen and his caddie Geno Bonnalie, as they are set to become the brand ambassadors for the company's new golf sunglasses. The duo will be sporting Knockaround's first-ever golf-specific shades, Flight Paths, equipped with Knockterra+ color-enhancing lenses. The company's CEO, Jeffrey R. Hennion, expressed excitement over the collaboration, emphasizing the perfect fit of the ambassadors with the brand's identity and the potential expansion of their popularity with the upcoming release of Full Swing 2 on Netflix. The golf collection, featuring the new lens technology, is scheduled for release in early February, offering both Knockterra and Knockterra+ options. Stay updated on Knockaround's golf venture through their social media channels and website. Knockaround Joel Dahmen Golf Sunglasses Flight Paths Knockterra+ Lenses
Published on 12/05/2025 at 02:35, 4 hours 32 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 6 hours 7 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 2 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 7 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 3 hours 36 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 16 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 41 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 52 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 56 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 13 hours 7 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 22 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 13 hours 23 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 13 hours ago Declaration of voting rights at the end of November 2025